Stacy Loeb, MD, discusses modern prostate cancer screening, emphasizing the transformative impact of MRI and the evolving guidelines. She highlights the shift in American Urological Association (AUA) recommendations, now aligning with the National Comprehensive Cancer Network (NCCN) to start baseline PSA testing between ages 45 and 50. Loeb underscores the importance of baseline PSA in the 40s for long-term risk prediction, especially for men without known risk factors. She advocates for risk-adapted screening, using factors like family history and PSA levels to tailor screening intervals. Shared decision-making is a unifying principle across guidelines, ensuring patient understanding of risks and benefits. Loeb addresses misconceptions, debunking myths like biopsies spreading cancer and early symptoms of prostate cancer. She recommends lifestyle factors such as reduced red meat and dairy intake, more plant-based foods, regular exercise, and good sleep for prevention. Looking ahead, Loeb predicts precision prevention and genetic-based personalized screening will shape the future of prostate cancer care. She encourages urologists to provide reliable, evidence-based resources and engage publicly to counter misinformation.
